Competition sharpens on active ingredient production – EU weighs measures
A new EU report investigates potential paths to securing more API production in the region, while making note of ”increased competition between countries.”
by christian bundgaard, translated by daniel pedersen
Both the US and the EU seek to onshore active pharmaceutical ingredient (API) manufacturing, writes industry media Endpoints News. Earlier this month, the EU published a report weighing the pros and cons of moving API production out of Europe, which came up short on cons.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
